Bioisosterism: A Useful Strategy for Molecular Modification and Drug Design

Lima, L�dia Moreira; Barreiro, Eliezer J.
January 2005
Current Medicinal Chemistry;2005, Vol. 12 Issue 1, p23
Academic Journal
This review aim to demonstrate the role of bioisosterism in rational drug design as well as in the molecular modification and optimization process aiming to improve pharmacodynamic and pharmacokinetic properties of lead compounds.


Related Articles

  • Modification of pharmacokinetics of norfloxacin following oral administration of curcumin in rabbits. Pavithra, B. H.; Prakash, N.; Jayakumar, K. // Journal of Veterinary Science;2009, Vol. 10 Issue 4, p293 

    investigation was carried out in adult New Zealand white rabbits to study the influence of curcumin pre-treatment on pharmacokinetic disposition of norfioxacin following single oral administration. Sixteen rabbits were divided into two groups of eight each consisting of either sex. Animals in...

  • A Perspective on Reconciling Mass Balance in Forced Degradation Studies. Lukulay, Patrick; Hokanson, Gerard // Pharmaceutical Technology;Oct2005, Vol. 29 Issue 10, p106 

    Focuses on two scenarios that demonstrate the need to use the percent of parent drug loss rather than the percent of degradation products formed when reconciling mass balance calculations. Quality control check on analytical methods to show that all degradation products are adequately detected...

  • Pharmacokinetics. Vohr, Hans-Werner // Encyclopedic Reference of Immunotoxicology;2005, p495 

    A definition of the term "pharmacokinetics" is presented. It refers to the study of bodily absorption, distribution, metabolism, and excretion of drugs.

  • Zero-order Kinetic.  // Encyclopedic Reference of Molecular Pharmacology;2004, p1017 

    A definition of the term "Zero-order Kinetic" is presented. It refers to the time course of disappearance of drugs from the plasma, which do not follow an exponential pattern, but are initially linear. This rare time course of elimination is most often caused by saturation of the elimination...

  • Maraviroc potential drug-drug interactions.  // Reactions Weekly;6/21/2008, Issue 1207, p5 

    The article discusses research being done on the major enzymes responsible for maraviroc metabolism. It references a study by R. Hyland et al., published in the "British Journal of Clinical Pharmacology" in 2008. The researchers found that maraviroc is predominantly metabolized by the CYP3A4...

  • Pharmacokinetics of an injectable long-acting formulation of doxycycline hyclate in dogs. Guti‚rrez, Lilia; Velasco, Zazil-Ha; V zquez, Carlos; Vargas, Dinorah; Sumano, H‚ctor // Acta Veterinaria Scandinavica;2012, Vol. 54 Issue 1, p35 

    Based on its PK/PD ratios, doxycycline hyclate (DOX-h), a time-dependant antibacterial, is ideally expected to achieve both sustained plasma drug concentrations at or slightly above the MIC level for as long as possible between dosing intervals. Pursuing this end, a poloxamer-based matrix was...

  • Clinical Pharmacokinetics and Metabolism of Bevantolol. Latts, Jeffrey R. // Angiology;Mar1986 Part 2, Vol. 37 Issue 3, p221 

    Bevantolol (the hydrochloride salt) has pharmacokinetic properties that are clinically advantageous. Bevantolol is well absorbed orally (> 70%); and the systemic bioavailability is 60%. Peak plasma concentrations are achieved 1 to 2 hours following an oral dose. Elimination is first-order with...

  • Impact of Oral Administration of the Surface-Active Excipient Solutol HS 15 on the Pharmacokinetics of Intravenously Administered Colchicine. Bittner, B.; Gonz�lez, R. C. Bravo; Walter, I.; Huwyler, J. // Letters in Drug Design & Discovery;May2005, Vol. 2 Issue 3, p193 

    Formulation ingredients may influence the pharmacokinetics of co-administered drugs. We investigated whether oral pre-dosing with the 'inactive' formulation ingredient Solutol affects the pharmacokinetic profile of intravenously administered colchicine in rats. Colchicine was administered...

  • Effect of Fluvoxamine on the Pharmacokinetics of Roflumilast and Roflumilast N-Oxide. von Richter, Oliver; Lahu, Gezim; Huennemeyer, Andreas; Herzog, Rolf; Zech, Karl; Hermann, Robert // Clinical Pharmacokinetics;2007, Vol. 46 Issue 7, p613 

    OBJECTIVE: To investigate the effects of steady-state dosing of fluvoxamine, an inhibitor of cytochrome P450 (CYP) 1A2 and CYP2C19, on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 (PDE4) inhibitor and its pharmacodynamically active metabolite roflumilast N-oxide. ...


Other Topics